Drug Type Biosimilar, Monoclonal antibody |
Synonyms Ipilimumab Biosimilar (Wincal Biopharm Inc.), Ipilimumab Eye Drop(Wincal Biopharm), 伊匹木单抗滴眼液(Wincal Biopharm) + [1] |
Target |
Action inhibitors |
Mechanism CTLA4 inhibitors(Cytotoxic T-Lymphocyte-Associated Antigen 4 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |


| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Uveal Melanoma | Preclinical | United States | 22 May 2023 |






